![]() Study participants had an average age of 64 years and percentage predicted FEV 1 of 51.5% (medians of study means). In each study, between 54% and 91% (median 70%) of participants were males. The median number of participants per study was 700. This review updates the first version of the review, published in 2017, and increases the number of included studies from 11 to 19 (22,354 participants). This review should be updated again in a few years. The results from future or ongoing trials evaluating newly developed medicines are awaited. This review is up to date to 10 September 2022. Our confidence in the evidence was moderate to high because the included studies were well-designed and had a sufficient number of participants with mainly moderate to severe COPD. What are the limitations of the evidence? People in each of the treatment groups reported similar quality of life scores and were about as likely to experience serious side effects, which were rare. LAMA+LABA probably made little to no difference to COPD exacerbations (flare-ups) compared to LABA+ICS. Pharmaceutical companies were involved in most of the studies, which might affect how much we can trust the results.Ĭompared to LABA+ICS, LAMA+LABA led to an improvement in lung function, reduced pneumonia from 5% to 3% but increased the risk of death from 1% to 1.4%. ![]() Most studies included people with moderate to severe COPD. The studies included more men than women (approximately 70% of participants were men), and the people in the studies were about 64 years old. We included 19 studies involving 22,354 participants. We summarised these results and rated our confidence in the evidence. We searched for trials that explored the benefits and harms of LAMA+LABA and LABA+ICS for the treatment of people with COPD. We examined the findings of trials that randomised people to receive either LAMA+LABA or LABA+ICS to see how they compare. Corticosteroids are anti-inflammatory medicines. Healthcare guidelines now recommend that people with stable, high-risk COPD use inhalers containing either a combined LAMA+LABA medicine or a combined LABA plus inhaled corticosteroid (LABA+ICS) medicine. Two key types of bronchodilator medicines are long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs). phlegm), and difficulty breathing.ĬOPD is treated with medications called 'bronchodilators' that make breathing easier by relaxing the muscles in the lungs and widening the airways. What is chronic obstructive pulmonary disease, and how is it treated?Ĭhronic obstructive pulmonary disease (COPD) is a long-term lung condition characterised by cough, sputum production (fluids from the lungs, i.e. The risk of death was slightly higher in people taking LAMA+LABA.LAMA+LABA and LABA+ICS probably work as well as each other in reducing COPD exacerbations and improving quality of life.Using an inhaler containing a long-acting muscarinic antagonist plus a long-acting beta-agonist (LAMA+LABA) for chronic obstructive pulmonary disease (COPD) probably improves respiratory function and reduces the risk of pneumonia compared to LABA plus an inhaled corticosteroid (LABA+ICS).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |